Anu Jayaram

#Opinion @AideenODoc, Assistant Professor in Accounting here in DCU Business School believes Shannon gas plan would make mockery of Irish climate goals♻️ Read the full #article here: irishtimes.com/opinion/shanno… @DCU @TeamDCU

💡Will #ctDNA serve as a treatment response biomarker in metastatic cancers? Here’s a thorough evaluation in @CCR_AACR from the RECIST working group, looking at the next steps towards using ctDNA for novel early endpoints in clinical trials and beyond. 👉 doi.org/10.1158/1078-0…

A prominent theme in our ongoing #Stampede work is survivorship. Important data on long term bone and CV data being presented at #ESMO2023 @MRCCTU @ICR_London

New research from @uclh @ucl & @KingsCollegeLon has found that #MRI can help detect prostate cancers missed by blood (PSA) tests. uclhospitals.brc.nihr.ac.uk/news/mri-scans… @mrsprostate @EmbertonMark @UCLDivofSurgery @uclcancer @BMJOncology

Find out @AttardLab’s latest publication (nature.com/articles/s4146…) showing that lethal prostate cancer progresses to lethal disease via a limited number (two or three) of dominant clones, each harbouring patient-specific androgen receptor gene architectures.

Abs#5056 #ASCO23 @ASCO: Matched ctDNA & tumour profiling in TALAPRO-2 (1L mCRPC ENZA + TALA vs ENZA + PBO) shows very high (95%) agreement. ctDNA also resolved cases where tumour HRR status was unknown. My take: We need ctDNA to deliver precision medicine optimally for PCa!

Happy #InternationalWomenAndGirlsinScienceDay! We are so proud to support so many brilliant #WomenInScience making cutting edge advances in #ProstateCancer research! @PCFnews @urotoday

Can an integrative approach reliably detect urine tumor DNA in localized #bladdercancer patients? We addressed this in our latest paper, out now in @Nature_npj Precision Oncology. nature.com/articles/s4169… @ZacharySmithMD @WashU_Uro @WashURadOnc @WashU_ctDNA @WashUDPS 1/15

Great opportunity for a trainee oncologist to join our team and become an expert on prostate cancer: atsv7.wcn.co.uk/search_engine/…

The scope and scale of this study from @marina_parry @AttardLab is just immense. Congratulations to the research team for a Herculean effort! #STAMPEDE @PCF_Science

IBCN Webinar Series continues with another high impact presentation by @ResearchWyatt regarding ctDNA in metastatic setting! Powerhouse talks and impressive attendance with leaders in bladder cancer!

Great coverage in The Times today about our high risk M0 results. Hopefully will help to get the treatment available in the NHS facebook.com/712334260/post…

Great presentation describing the latest from the STAMPEDE trial by GU Member Gerhardt Attard @AttardLab during the Presidential symposium 2 at #ESMO21. Significant results with an extremely encouraging benefit for patients with improved MFS and OS. #MedEd #prostatecancer

#ESMO21 : Impressive results of the STAMPEDE trial with a great benefit of ADT + AAP +/- ENZ vs. ADT alone in terms of MFS (HR = 0.53) and OS (HR = 0.60)!! @myESMO @OncoAlert

Listen to the @Uromigos podcast describing the latest STAMPEDE data shown at #ESMO21

Excited to share the latests results from the STAMPEDE clinical trial: abiraterone plus prednisolone with or without enza added to ADT compared to ADT alone in high risk nonmetastatic #prostatecancer patients #ESMO21

Please join our next 48-hour #ProstateJC starting tomorrow, 4/27 at 10am ET! We will be discussing plasma tumor gene conversions after one cycle of abiraterone as a biomarker in patients with metastatic castration-resistant #ProstateCancer. #openaccess sciencedirect.com/science/articl…

Please check out our paper from @AttardLab looking at the value of plasma DNA analysis after four weeks of treatment authors.elsevier.com/a/1cy8c3I2OQXF…

Our trial comparing cabazitaxel to ARPI in poor prognosis ARPI-naïve mCRPC published in @Annals_Oncology: bit.ly/3fR4I1M. Thanks to all investigators in Can/Aus, and funding support for enabling this 5+ year effort! Thread 👇on outcomes and ctDNA correlatives. 1/5